Schedule III controlled substances.

Pursuant to section 3719.41 of the Revised Code, controlled substance schedule III is hereby established, which schedules include the following, subject to amendment pursuant to section 3719.43 or 3719.44 of the Revised Code.

(A) Stimulants

Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, their optical isomers, position isomers, or geometric isomers, and salts of these isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

1. All stimulant compounds, mixtures, and preparations included in schedule III pursuant to the federal drug abuse control laws and regulations adopted under those laws;
2. Benphetamine;
3. Chlorphentermine;
4. Clortermine
5. Phendimetrazine.

(B) Depressants

Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:

1. Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs, and one or more other active medicinal ingredients that are not listed in any schedule;
2. Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the food and drug administration for marketing only as a suppository;
3. Any substance that contains any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid;
(4) Chlorhexadol;

(5) Embutramide;

(6) Any dangerous drug containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (8/20/2019);

(7) Ketamine, its salts, isomers, and salts of isomers (some other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);

(8) Lysergic acid;

(9) Lysergic acid amide;

(10) Methyprylon;

(11) Sulfondiethylmethane;

(12) Sulfonethylmethane;

(13) Sulfonmethane;

(14) Tiletamine, zolazepam, or any salt of tiletamine or zolazepam (some trade or other names for a tiletamine-zolazepam combination product: Telazol); (some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3, 4-e][1,4]diazepin-7(1H)-one; flupyrazapon).

(C) Narcotic antidotes

(1) Nalorphine.

(D) Narcotics-narcotic preparations

Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoine alkaloid of opium;
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(4) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(7) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

(a) Buprenorphine.

(E) Anabolic steroids

Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including their salts, esters, isomers, and salts of esters and isomers, whenever the existence of these salts, esters, and isomers is possible within the specific chemical designation:

(1) Anabolic steroids. Except as otherwise provided in paragraph (E)(1) of this rule, "anabolic steroids" means any drug or hormonal substance that is chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) and that promotes muscle growth. "Anabolic steroids" does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the United States secretary of health and human services for that administration, unless a person prescribes, dispenses, or distributes this type of anabolic steroid for human use. "Anabolic steroid" includes, but is not limited to, the following:
(a) 3beta,17-dihydroxy-5a-androstane;
(b) 3alpha,17beta-dihydroxy-5a-androstane;
(c) 5alpha-androstan-3,17-dione;
(d) 1-androstenediol (3beta,17beta-dihydroxy-5a-androst-1-ene);
(e) 1-androstenediol (3alpha,17beta-dihydroxy-5a-androst-1-ene);
(f) 4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);
(g) 5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);
(h) 1-androstenedione ([5alpha]-androst-1-en-3,17-dione);
(i) 4-androstenedione (androst-4-en-3,17-dione);
(j) 5-androstenedione (androst-5-en-3,17-dione);
(k) bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
(l) boldenone (17beta-hydroxyandrost-1,4-diene-3-one);
(m) boldione (androsta-1,4-diene-3,17-dione);
(n) calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
(o) clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one);
(p) dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);
(q) desoxymethyltestosterone (17alpha-methyl-5alpha-androst-2-en-17beta-ol) (a.k.a. 'madol');
(r) delta 1-dihydrotestosterone (a.k.a.'1-testosterone') (17beta-hydroxy-5alpha-androst-1-en-3-one);
(s) 4-dihydrotestosterone (17beta-hydroxy-androstan-3-one);
(t) drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
(u) ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);
fluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);

formebolone (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-dien-3-one);

furazabol (17alpha-methyl-17beta-hydroxyandrostan[2,3-c]-furazan);

13beta-ethyl-17beta-hydroxygon-4-en-3-one;

4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);

4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);

mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);

mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);

methandienone (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);

methandriol (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);

methasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);

methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);

17alpha-methyl-3beta,17beta-hydroxy-5a-androstane;

17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;

17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene;

17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);

methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);

methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9,11-trien-3-one);

methyltestosterone (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);

mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
(pp) 17alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-
methyl-5alpha-androst-1-en-3-one) (a.k.a. '17-alpha-methyl-1-
testosterone');

(qq) nandrolone (17beta-hydroxyestr-4-en-3-one);

(rr) 19-nor-4-androstenediol (3beta, 17beta-dihydroxyestr-4-ene);

(ss) 19-nor-4-androstenediol (3alpha, 17beta-dihydroxyestr-4-ene);

(tt) 19-nor-5-androstenediol (3beta, 17beta-dihydroxyestr-5-ene);

(uu) 19-nor-5-androstenediol (3alpha, 17beta-dihydroxyestr-5-ene);

(vv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

(ww) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(xx) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(yy) norbolethone (13beta, 17alpha-diethyl-17beta-hydroxygon-4-en-3-one);

(zz) norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);

(aaa) norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);

(bbb) normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);

(ccc) oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-
androstan-3-one);

(ddd) oxymesterone (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);

(eee) oxymetholone (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-
[5alpha]-androstan-3-one);

(fff) prostanazol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);

(ggg) stanozolol (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-
eno[3,2-c]-pyrazole);

(hhh) stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);

(iii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
lactone);
(jjj) testosterone (17beta-hydroxyandrost-4-en-3-one);

(kkk) tetrahydrogestrinone (13beta, 17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);

(lll) trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one);

(mmm) methandranone;

(nnn) Any salt, ester, isomer, or salt of an ester or isomer of a drug or hormonal substance described or listed in paragraph (E)(1) of this rule if the salt, ester, or isomer promotes muscle growth.

(F) Hallucinogenic substances

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product (some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol).
Replaces: 4729-11-03
Effective: 3/22/2020
Five Year Review (FYR) Dates: 03/22/2025

CERTIFIED ELECTRONICALLY

Certification

01/27/2020

Date

Promulgated Under: 119.03
Statutory Authority: 4729.26, 3719.28, 3719.41
Rule Amplifies: 3719.43, 3719.44
Prior Effective Dates: 09/01/2014